title: Proatherogenic macrophage activities are targeted by the flavonoid quercetin.
abstract: Many studies have demonstrated that the flavonoid quercetin protects against cardiovascular disease (CVD) and related risk factors. Atherosclerosis, the underlying cause of CVD, is also attenuated by oral quercetin administration in animal models. Although macrophages are key players during fatty streak formation and plaque progression and aggravation, little is known about the effects of quercetin on atherogenic macrophages. Here, we report that primary bone marrow-derived macrophages internalized less oxidized low-density lipoprotein (oxLDL) and accumulated less intracellular cholesterol in the presence of quercetin. This reduction of foam cell formation correlated with reduced surface expression of the oxLDL receptor CD36. Quercetin also targeted the lipopolysaccharide-dependent, oxLDL-independent pathway of lipid droplet formation in macrophages. In oxLDL-stimulated macrophages, quercetin inhibited reactive oxygen species production and interleukin (IL)-6 secretion. In a system that evaluated cholesterol crystal-induced IL-1β secretion via nucleotide-binding domain and leucine-rich repeat containing protein 3 inflammasome activation, quercetin also exhibited an inhibitory effect. Dyslipidemic apolipoprotein E-deficient mice chronically treated with intraperitoneal quercetin injections had smaller atheromatous lesions, reduced lipid deposition, and less macrophage and T cell inflammatory infiltrate in the aortic roots than vehicle-treated animals. Serum levels of total cholesterol and the lipid peroxidation product malondialdehyde were also reduced in these mice. Our results demonstrate that quercetin interferes with both key proatherogenic activities of macrophages, namely foam cell formation and pro-oxidant/proinflammatory responses, and these effects may explain the atheroprotective properties of this common flavonoid.
authors.affiliation: Grupo Inmunomodulacion, Facultad de Medicina, Sede de Investigación Universitaria, Universidad de Antioquia, Cra 53 No 61-30, Medellín, Colombia.
authors.forename: Oscar J
authors.initials: OJ
authors.lastname: Lara-Guzman
authors.forename: Jorge H
authors.initials: JH
authors.lastname: Tabares-Guevara
authors.forename: Yudy M
authors.initials: YM
authors.lastname: Leon-Varela
authors.forename: Rafael M
authors.initials: RM
authors.lastname: Álvarez
authors.forename: Miguel
authors.initials: M
authors.lastname: Roldan
authors.forename: Jelver A
authors.initials: JA
authors.lastname: Sierra
authors.forename: Julian A
authors.initials: JA
authors.lastname: Londoño-Londoño
authors.forename: Jose R
authors.initials: JR
authors.lastname: Ramirez-Pineda
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001057:Apolipoproteins E / Q000235:genetics; D050197:Atherosclerosis / Q000473:pathology* / Q000517:prevention & control*; D018955:CD36 Antigens / Q000096:biosynthesis / Q000235:genetics; D002784:Cholesterol / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004032:Diet; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005487:Foam Cells / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000473:pathology; D050356:Lipid Metabolism / Q000235:genetics / Q000502:physiology; D008264:Macrophages / Q000187:drug effects / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010084:Oxidation-Reduction; D011794:Quercetin / Q000494:pharmacology*; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D000975:Antioxidants; D001057:Apolipoproteins E; D018955:CD36 Antigens; D008078:Cholesterol, LDL; D016207:Cytokines; D017382:Reactive Oxygen Species; D002784:Cholesterol; D011794:Quercetin